• EN

Denmark country overview — a summary of the national drug situation



Denmark country overview
A summary of the national drug situation

Map of Denmark

Our partner in Denmark

The Danish focal point is located within the National Board of Health (NBH), an autonomous Government agency linked to the Ministry of Health. The National Board of Health is made up of a number of divisions and centres, each dealing with its own area of expertise. Read more »

Danish Health and Medicines Authority

Danish Health and Medicines Authority
Axel Heides Gade 1
DK- 2300, Copenhagen S
Tel. +45 72227760
Fax +45 72227411

Head of focal point: Ms Kari Grasaasen

Our partner in Denmark

Danish Health and Medicines Authority

Danish Health and Medicines Authority
Axel Heides Gade 1
DK- 2300, Copenhagen S
Tel. +45 72227760
Fax +45 72227411

Head of focal point: Ms Kari Grasaasen

The Danish focal point is located within the National Board of Health (NBH), an autonomous Government agency linked to the Ministry of Health. The National Board of Health is made up of a number of divisions and centres, each dealing with its own area of expertise.

E-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses.

Drug use among the general population and young people

The latest survey among the general population (16 years and over, using a multi-method) was carried out in 2013. The sample size consisted of 10 740 people aged 16–64. Previous surveys were conducted in 1990, 2000, 2005, 2008 and 2010. In the 2013 survey the lifetime prevalence of cannabis use was 35.6 %, followed by amphetamines at 6.6 % and cocaine at 5.2 %. Last year prevalence of cannabis use was 6.9 %, and last month prevalence was 2.7 %. One in two young adults aged 16–34 had ever tried cannabis (lifetime prevalence of 45.9 %), while one in 10 had ever tried amphetamines or cocaine. About 17.6 % of young adults reported using cannabis in the last year and 6.4 % reported using it in the last month. These data, when compared to previous studies, indicate a slight upward trend in cannabis use among young adults since 2010. The survey also indicates a decreasing trend in amphetamines and ecstasy use among young people aged 16–24 since 2000, while cocaine use remained reasonably stable during that period among this age group.

The survey also examined the prevalence of ketamine and GHB use, and found that less than 1 % of 16- to 24-year-olds reported recent use of these new substances.

The European School Survey Project on Alcohol and Other Drugs (ESPAD) has been conducted regularly in Denmark since 1995 among students aged 15–16. Trends show that lifetime prevalence of illicit drugs increased between 1995 and 1999, stabilised between 1999 and 2003, and in 2007 showed a slight yet significant increase. However, the most recent study from 2011 indicates a significant reduction in lifetime prevalence rates for the most common illicit drugs among 15- to 16-year-olds. The lifetime prevalence of cannabis use in 2011 was 18 % (23 % in 2003; 25 % in 2007), amphetamines was 2 % (4 % in 2003; 5 % in 2007), cocaine was 2 % (2 % in 2003; 3 % in 2007) and ecstasy was 1 % (2 % in 2003; 5 % in 2007). Inhalants were the second most reported substance used, at 4 %, and a decline in lifetime prevalence rates was also noted in 2011 (8 % in 2003; 6 % in 2007). In general, more males than females had tried cannabis and amphetamines, while as many males as females reported ever having tried cocaine and heroin; however, ecstasy and hallucinogens had been tried by more females than males.

In 2010 a nightlife survey was carried out by the Centre for Alcohol and Drug Research of Aarhus University, which indicated that more than half of nightclub visitors had ever used cannabis, while about 40 % had used an illicit substance other than cannabis. Polydrug use is common in these settings, when a mix of illicit and licit substances is used.

Look for Prevalence of drug use in the 'Statistical bulletin' for more information  

High-risk drug use

Up to 2012 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defined problem drug use as injecting drug use (IDU) or long duration/regular use of opiates, cocaine and/or amphetamines. However, in 2012 a new definition of ‘high-risk drug use’ was adopted. The new definition includes ‘problem drug use’, but is broader (mainly in its inclusion of high-risk use of more substances). Details are available here.

The latest estimate of the number of problem drug users in Denmark was carried out in 2009, applying the capture–recapture method and including two data sources, the National Registry of Patients and the National Register of Drug Users Undergoing Treatment. Problem drug users were defined as those reporting persistent use of illicit drugs, including cannabis, which leads to physical, psychological and social consequences. The total number of problem drug users was estimated at 33 074 (sensitivity interval: 31 151–34 997), which corresponds to a rate of 9.12 per 1 000 population aged 15–64 (sensitivity interval: 8.59–9.65). Compared to the estimates from 2001, 2003 and 2005, the number of problem drug users appears to be increasing.

Based on the general population survey, it is estimated that about 0.4 % of the Danish population aged 15–64 used cannabis daily or almost daily in 2013. The latest capture–recapture estimate suggested that there were about 10 900 problem cannabis users in 2009.

The number of people who injected drugs in 2006 was estimated to be about 13 000 (sensitivity interval: 10 066–16 821).

Look for High risk drug-use in the Statistical bulletin for more information.  

Treatment demand

Up to 2011 data on treatment demand was collected by the National Board on Health, and after 2011 by the National Board of Social Services (NBSS). The NBSS collects data on treatment, managing the register of drug users in treatment, which is a combined reporting portal for all relevant authorities collecting treatment data. This move to a merged register has required technical changes that caused delay in data collection. For that reason the last available data from Denmark are from 2011.

In 2011 treatment demand data were reported from 130 of 145 treatment units. Approximately 5 686 clients entered treatment, of which 1 847 were new clients entering treatment for the first time.

Cannabis was the most frequently reported primary drug among all treatment clients in 2011, at 63 %, followed by opioids at 18 % and amphetamines at 10 %. Cannabis was the most frequently reported primary drug by a larger proportion of new treatment clients, at about 73 %, followed by amphetamines at 10 % and opioids at 7 %. Overall injection rates among treatment clients are low; however, among those with primary opioids use about one-third reported injecting the substance, while less than a quarter of new opioid-related treatment clients reported injecting behaviour.

In 2011 some 37 % of all treatment clients were under the age of 25, while new treatment clients tended to be younger, with 54 % under 25. In 2011 the male to female ratio for all clients entering treatment and new clients entering treatment was similar, at approximately three to one.

Look for Treatment demand indicator in the Statistical bulletin for more information.  

Drug-related infectious diseases

Human immunodeficiency virus (HIV) infections are registered by the State Serum Institute, based on anonymous reporting and voluntary testing. In 2013 a total of 13 newly diagnosed HIV-positive cases and five new acquired immune deficiency syndrome (AIDS) cases in people who inject drugs (PWID) were reported.

Two of 19 cases of acute hepatitis B virus (HBV) infection and seven of 264 chronic HBV infections with a known transmission route were attributed to injecting drug use in 2013. For hepatitis C virus (HCV) infections, five of 11 acute cases and153 of 218 chronic cases with a known transmission route were attributed to injecting drug use.

A special study from 2004–08 indicated that the HIV prevalence level among PWID was 2.1 %. In the same study, around 37.1 % of a sample of PWID tested positive for aHBc (anti-Hepatitis B core antigen), and the prevalence of HCV among PWID was around 52.5 %. However, these results should be interpreted with caution as the users tested were not representative of PWID in Denmark.

Look for Drug-related infectious diseases in the Statistical bulletin for more information.  

Drug-induced deaths and mortality among drug users

Drug-induced deaths are recorded in the register of the National Police Register and the Cause of Deaths Register of the State Serum Institute. Data extraction and reporting from the Cause of Deaths register is in line with the EMCDDA definitions and recommendations. This implies the use of the X44, X64 and Y14 codes that are constitutive of Selection B. The National Police Register collates all death cases reported to police for the purpose of post-mortem examination. In a Danish context (not for international comparisons), it constitutes an important source of information for the analysis of developments overt time.

According to the Cause of Deaths Register, in 2012 there were 244 drug-induced deaths in Denmark. With regard to gender, males prevail (167 deaths). The mean age of victims was 46.9 years. Toxicological results were known for 237 deaths, and the majority of them (202 cases) were linked to opioids.

Based on these data, the drug-induced mortality rate among adults (aged 15–64) was 60.1 deaths per million in 2011, more than the European average of 17.2 deaths per million in 2012.

The data from the Police Register suggests a total of 213 drug-related deaths, which is the lowest number recorded since 1994. Of these 213 deaths a total of 164 were caused by drug poisoning, of which 135 were related to opioids. The presence of methadone was reported in about 70 % of these cases, and in almost all cases more than one psychoactive substance was involved. There was a decline in the number of deaths where heroin/morphine is reported and an increase in the proportion of deaths where methadone is assumed to be the most significant cause of death.

Look for Drug-related deaths in the Statistical bulletin for more information.  

Treatment responses

The main goals of Danish drug treatment policy are to achieve a reduction in drug use or to attain full abstinence through enhanced use of psychosocial interventions and systematic follow-up of treatment, and to tackle problems other than those of drug use. Following local government reform in 2007 municipalities became responsible for organising both the social and medical treatment of drug users. While the 98 municipalities are responsible for drug treatment, the five regions are responsible for psychiatric, primary and public healthcare. The Social Services Administration is responsible for referring a person for medical and social treatment for drug use, and the preparation of his/her treatment plan is a mandatory action according to the Social Service Act. Access to drug treatment is guaranteed within 14 days of the first contact or request from drug users over the age of 18, and in some cases aged under 18. People who are entitled to treatment may choose between public and private treatment programmes within a framework of a prescribed treatment plan.

Clients are usually treated as outpatients, and this may be supplemented by day or inpatient treatment if a change in environment and/or a more structured intervention is needed. The most prevalent approaches to treatment in Denmark are cognitive, socio-educational and solution-focused. Treatment for opioid users is predominantly medically assisted and is accompanied by psychosocial counselling. In recent years new initiatives such as a cannabis and cocaine project in Copenhagen city have been developed to tackle a specific demand for the treatment of cannabis and cocaine users, and several initiatives to address socially marginalised drug users, drug users with concurrent mental disorders, and underage youth are also supported.

Opioid substitution treatment (OST) is provided free of charge, primarily at specialised outpatient treatment units provided by local Social Services Administrations in municipalities. Methadone, which has been available in Denmark since 1970, is the predominant substance; buprenorphine is offered alongside methadone and the National Board of Health’s guidance (currently the Danish Health and Medicines Authority) issued in 2008 recommends it as the first-line medication for opioid-dependent drug users that have not previously been treated. Figures from 2011, the latest available estimates, show that 7 600 clients were on OST, of whom 6 200 were on methadone and 1 400 on buprenorphine. As part of the treatment provided to the most seriously affected heroin abusers, in January 2010 the government initiated a scheme of treatment using medically prescribed heroin, and 198 drug users were in injectable heroin treatment by April 2013. In spring 2013 the treatment scheme was evaluated, and as a follow-up a treatment option with tableted heroin started in October 2013.

See the Treatment profile for Denmark for additional information.  

Harm reduction responses

In addition to treatment services, projects have been implemented to reduce or minimise drug-related harm among high-risk drug users. Such projects include, for example, outreach street work, drop-in centres, needle and syringe programmes and social support at home. Needle and syringe programmes have been established in Denmark since 1986. The number of syringes given out by these programmes is not being monitored, but a 2009 evaluation confirmed that drug users had high levels of access to clean injecting equipment across municipalities. The services are administered either through free dispensing of syringes and syringe sales at pharmacies, through treatment institutions, in drop-in centres or through syringe dispensing machines at public sites. Some municipalities also dispense needles and syringes at shelters and hostels. The provision of sterile water and other the injecting equipment is common. Since 2013 a naloxone take-home programme to prevent opioid-induced deaths has been implemented in four municipalities. In three municipalities (Copenhagen, Aarhus and Odense) supervised drug consumption facilities operate on the basis of legal provisions made in 2012. These facilities serve injecting drugs users, while some are adjusted also to serve those who smoke drugs.

In 2007 the National Board of Health adopted a special action plan for the prevention of HCV. As a result, by 2009 most municipalities had launched a number of specific actions, such as counselling, screening and vaccination against hepatitis A virus and HBV. Recently, programmes facilitating marginalised drug users’ access to general health services have also been implemented. Active referral of newly detected HIV, HBV and HCV cases for further examination, counselling and treatment is also encouraged.

See the Harm reduction overview for Denmark for additional information.  

Drug markets and drug-law offences

Morocco continues to be the primary producing country of the cannabis resin that reaches the Danish market, with Spain, Portugal and the Netherlands being the main transit countries. The vast majority of heroin is reported as originating in Afghanistan and Pakistan. Amphetamines and ecstasy seized in Denmark are produced in the Netherlands and Belgium and, to a minor extent, in Poland and the Baltic states. Cocaine seized in Denmark is produced in South America and distributed via the Netherlands and Spain. However, the importance of trafficking routes via the West African and Baltic regions has increased in recent years.

A total of 24 058 drug offence reports were registered in 2013, the highest annual number ever reported.

The National Commissioner of Police Statistics indicates that the number of seizures and the quantity seized fluctuate, and are affected by bulk seizures and police activity. In 2013 the total number of drug seizures, except cannabis plants, increased when compared to 2013 figures. The amounts of seized cannabis products, cocaine and amphetamine increased when compared to 2013 data, while methamphetamine stayed at the level of 2012, but the amounts of heroin and ecstasy seized were below the level of 2011. The record amounts of 3 292 kg of cannabis resin, 394 kg of herbal cannabis and 5 634 cannabis plants were seized. A dramatic increase in the amount of cocaine seized was reported in 2013, when 681 kg of the substance was seized. This increase is explained by a few major seizures. In 2013 a record amount of 340 kg of amphetamine was seized (302 kg in 2012; 255 kg in 2011; 194 kg in 2010). Following the high number of ecstasy tablets seized in 2012 (72 654), in 2013 seizures of only 7 706 ecstasy tablets were reported. Fourteen kilograms of heroin were seized in Denmark, which is the lowest quantity in past seven years.

Look for Drug law offences in the Statistical bulletin for additional data.  

National drug laws

According to the Consolidated Euphoriant Substances Act of 2008, import, export, sale, purchase, delivery, receipt, production, processing and possession of drugs are defined as criminal offences. The penalty under this Act is a fine or imprisonment for a maximum of two years. Use itself is not mentioned as an offence. Illegal possession for own use usually involves a fine, which varies depending on the type and quantity of drugs involved. In some cases the possession of dangerous drugs for the purpose of own use may also result in short-term imprisonment. The Act had already been amended in 1996 to increase the penalty for professional drug dealers, who had previously avoided serious sanctions by only carrying very small quantities of drugs at a time. From 2004 the distribution of drugs in restaurants, discotheques or similar places frequented by children or young people has been deemed to be a significantly aggravating circumstance that should always be punished with a prison sentence.

More serious offences are punished under Section 191 of the Criminal Code. The precondition for resorting to this instead of the Euphoriant Substances Act is that the criminal offence involves the transfer of, or the intention to transfer, at least 25 g of heroin or cocaine, 50 g of amphetamine or 10 kg of cannabis. Since 2004 the penalty under Section 191 of the Criminal Code has been imprisonment for 10–16 years, with up to 25 years in particularly serious cases.

No alternatives to punishment are specified for drug-related offences. However, probationary measures can be applied at the sentencing stage, if the court finds punishment unnecessary (this may be applied in cases of any crime), and the law mentions an obligation to undergo treatment as one of these measures.

A new law to allow the medical prescription of heroin to addicts became effective on 1 July 2008, while in 2012 a law allowing the Minister of Health to grant permission for drug consumption rooms to be opened and operated came into effect.

On 1 July 2012 group bans on psychoactive substances came into force following the amendment of the Euphoriant Substances Act, so that Denmark will apply a ‘generic classification’ to control certain new psychoactive substances entering the country.

Go to the European Legal Database on Drugs (ELDD) for additional information.  

National drug strategy

Denmark’s national drug policy is comprehensive and covers prevention and early intervention, treatment, harm reduction and law enforcement. For the time being, Denmark does not have a national drug strategy document. However, the national drug policy is expressed in strategic documents in some policy areas and in legislation and concrete actions. As a result, Danish drug policy covers all relevant areas of a comprehensive approach to drug issues.


Coordination mechanism in the field of drugs

Denmark has no ‘formal’ drug coordination body. However, the Ministry of Health has responsibility for coordination in the drugs field at a central level. In Denmark coordination is based on frequent informal contact between relevant ministries. Among its drug-related tasks, the Ministry of Health is responsible for legislation related to psychoactive substances, controlling the legal use of drugs for medical and scientific purposes and overseeing government action in the field of prevention. The Ministry of Health, together with the Danish Health and Medicines Authority, is also responsible for the medical treatment of drug users. The Health and Medicines Authority issues authorisations to companies seeking to transport psychoactive substances for medical purposes and works with the International Narcotics Control Board in this respect. It also develops professional guidelines, monitors drug use through surveys of the population and the drug markets, and acts as the national focal point in the Reitox network. The Ministry of Social Affairs and Integration is responsible for providing support to drug users seeking assistance with housing, education and employment. Precursor control issues are the responsibility of the Ministry of Tax, while the Ministry of Foreign Affairs is tasked with international drug policy issues.

At a local level, municipalities are responsible for prevention, treatment and social reintegration measures for drug users. Municipalities work closely with the Ministry of Health in monitoring drug use and developing appropriate responses.

Public expenditure

In Denmark, multi-annual drug budgets are attached to the national action plan and have been implemented, since 2004, under the format of the Social Reserve Grants Agreement. Available data on drug-related public expenditures are multi-annual and include only labelled expenditures (1).

The Social Reserve Grants Agreement had a planned budget of EUR 19.5 million for drug-related initiatives between 2004 and 2007. In 2006 this budget was reinforced and a new budget of EUR 33.6 million was defined for the period 2006–09. This agreement was strengthened in 2008 and 2009, with an additional EUR 16.4 million. In 2011 another EUR 9.6 million was set aside. In 2012 EUR 3.2 million was budgeted for the years 2012–15. In 2013 the treatment of drug abuse was prioritised and a budget of EUR 13.8 million was assigned for the period 2013–18. At the level of local government, close to EUR 117 million were allocated to drug treatment in 2013; data for the budget of municipalities is still not available. In 2013 drug treatment in prisons continued to increase, reaching EUR 13.6 million.

The available information does not allow the drug-related annual public expenditure effectively spent and its evolution over time to be reported.

  • (1) Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, the bulk of drug-related expenditure is not identified (‘unlabelled’) and must be estimated by modelling approaches. The total budget is the sum of labelled and unlabelled drug-related expenditures.

Drug-related research

Drug-related research in Denmark is mainly funded by governmental grants and can be characterised as applied research, often based on the evaluation of public services. It is mainly commissioned by ministries and undertaken by academic centres and government institutes. Healthcare planning and priority setting are also primary concerns in this area and surveys are thus often initiated, and partially funded, by the national focal point at the Danish Health and Medicines Authority. Dissemination of results is ensured through a wide variety of channels, including reports, websites, conferences and thematic days. The Danish Health and Medicines Authority has also formulated a number of research-based principles on which schools should base their drug prevention interventions. Recent drug-related studies mentioned in the 2014 Danish National report mainly focused on aspects related to responses to the drug situation but topics including prevalence, incidence and patterns of use and supply and markets were also reported.

See Drug-related research for more detailed information. 

Key national figures and statistics

b Break in time series.

e Estimated.

p Eurostat provisional value.

1 Gross domestic product (GDP) is a measure of economic activity. It is defined as the value of all goods and services produced less the value of any goods or services used in their creation. The volume index of GDP per capita in Purchasing Power Standards (PPS) is expressed in relation to the European Union (EU-27) average set to equal 100. If the index of a country is higher than 100, this country's level of GDP per head is higher than the EU average and vice versa.

2  Expenditure on social protection contains: benefits, which consist of transfers, in cash or in kind to households and individuals to relieve them of the burden of a defined set of risks or needs.

3 Unemployment rates represent unemployed persons as a percentage of the labour force. Unemployed persons comprise persons aged 15 to 74 who were: (a) without work during the reference week; (b) currently available for work; (c) actively seeking work.

4 Situation of penal institutions on 1 September, 2012.

5 Share of persons aged 0+ with an equivalent disposable income below the at-risk-of-poverty threshold, which is set at 60 % of the national median equivalised disposable income (after social transfers).

Key figures
  Year   EU (28 countries) Source
Population  2014 5 627 235
506 824 509 ep Eurostat
Population by age classes 15–24  2014 12.9 % 11.3 % bep
25–49 32.5 % 34.7 % bep
50–64 19.1 % 19.9 % bep
GDP per capita in PPS (Purchasing Power Standards) 1  2013 124 100 Eurostat
Total expenditure on social protection (% of GDP) 2  2012 34.6 % 29.5 % p Eurostat
Unemployment rate 3  2014 6.6 % 10.2 % Eurostat
Unemployment rate of population aged under 25 years  2014 12.6 % 22.2 % Eurostat
Prison population rate (per 100 000 of national population) 4  2013 73.0  : Council of Europe, SPACE I-2013
At risk of poverty rate 5  2013 12.3 % 16.6 %  SILC

Data sheet — key statistics on the drug situation

        EU range      
  Year   Country data Min. Max. Average Rank Reporting Countries
Problem opioid use (rate/1 000) :   : 0.2 10.7      
All clients entering treatment (%) 2011   17.5% 6% 93%      
New clients entering treatment (%) 2011   7.1% 2% 81%      
Purity — heroin brown (%) 2013   19.0% 6% 42%   13 24
Price per gram — heroin brown (EUR) 2012   EUR 84 EUR 25 EUR 158   19 22
Prevalence of drug use — schools (%) 2011   2.0% 1% 5%      
Prevalence of drug use — young adults (%) 2013   2.4% 0% 4% 2%    
Prevalence of drug use — all adults (%) 2013   0.9% 0% 2% 1% 19 26
All clients entering treatment (%) 2011   5.1% 0% 39%      
New clients entering treatment (%) 2011   5.8% 0% 40%      
Purity (%) 2013   29.0% 20% 75%   3 27
Price per gram (EUR) 2012   EUR 66 EUR 47 EUR 103   14 24
Prevalence of drug use — schools (%) 2011   2.0% 1% 7%      
Prevalence of drug use — young adults (%) 2013   1.4% 0% 3% 1%    
Prevalence of drug use — all adults (%) 2013   0.6% 0% 1% 1% 15 25
All clients entering treatment (%) 2011   9.5% 0% 70%      
New clients entering treatment (%) 2011   10.3% 0% 22%      
Purity (%) 2013   9.0% 5% 71%   7 25
Price per gram (EUR) 2012   EUR 19 EUR 8 EUR 63   14 21
Prevalence of drug use — schools (%) 2011   1.0% 1% 4%      
Prevalence of drug use — young adults (%) 2013   0.7% 0% 3% 1%    
Prevalence of drug use — all adults (%) 2013   0.2% 0% 2% 1% 3 25
All clients entering treatment (%) 2011   0.3% 0% 2%      
New clients entering treatment (%) 2011   0.5% 0% 4%      
Purity (mg of MDMA base per unit) 2013   144 mg 26 mg 144 mg   23 23
Price per tablet (EUR) 2012   EUR 7 EUR 3 EUR 24   10 19
Prevalence of drug use — schools (%) 2011   18.0% 5% 42%      
Prevalence of drug use — young adults (%) 2013   17.6% 0% 22% 12%    
Prevalence of drug use — all adults (%) 2013   6.9% 0% 11% 6% 23 27
All clients entering treatment (%) :   63.4% 3% 63%      
New clients entering treatment (%) :   72.6% 5% 80%      
Potency — herbal (%) :   : 2% 13%      
Potency — resin (%) :   : 3% 22%      
Price per gram — herbal (EUR) :   : EUR 4 EUR 25      
Price per gram — resin (EUR) 2013   EUR 7 EUR 3 EUR 21   6 21
Prevalence of problem drug use                
Problem drug use (rate/1 000) 2009 1 9.1 2.0 10.0      
Injecting drug use (rate/1 000) :   : 0.2 9.2      
Drug-related infectious diseases/deaths                
HIV infections newly diagnosed (rate/million) 2013   2.3 0.0 54.5      
HIV prevalence (%) 2006   2.1% 0% 49%      
HCV prevalence (%) 2008   52.5% 14% 84%      
Drug-related deaths (rate/million) 2012   43.6 1.5 84.1      
Health and social responses                
Syringes distributed :   : 124 406 9 457 256      
Clients in substitution treatment 2011   7 600 180 172 513      
Treatment demand                
All clients 2011   5 686 289 101 753      
New clients 2011   1 847 19 35 229      
All clients with known primary drug 2011   3 779 287 99 186      
New clients with known primary drug 2011   1 444 19 34 524      
Drug law offences                
Number of reports of offences 2013   24 058 429 426 707      
Offences for use/possession :   : 58 397 713      


See the explanatory notes for further information on the methods and definitions.

Only the most recent data are available for each key statistic. Data before 2006 were excluded.

1 - The target population are clients admitted to treatment for their drug problems over all (including users of cannabis).

Additional sources of national information

In addition to the information provided above, you might find the following resources useful sources of national data.

Page last updated: Tuesday, 07 July 2015